CompletedNot Applicable

Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice

United States175 participantsStarted 2021-06-09

Plain-language summary

This was a retrospective cohort study using the electronic medical record (EMR) database from Cleveland Clinic. The data was analyzed at start of ofatumumab (OMB) therapy (baseline, defined as 6 months prior to OMB initiation) and at 6 or 12 months following initiation of OMB.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Patients who initiated OMB commercially from the time of disease modifying therapy (DMT) approval (August 2020), and * Aged 18 years or older at index date, and * Patients who met 2017 McDonald Criteria for clinically definite multiple sclerosis (MS), or * Patients diagnosed with clinically isolated syndrome (CIS) by Cleveland Clinic MS specialist. Exclusion criteria: Those who were participating in OMB clinical trials (e.g., ARTIOS, OLIKOS)

What they're measuring

Number of Patients Categorized by Number of Relapses

Timeframe: Baseline, Month 6, Month 12

Change in Relapse Rate From Baseline to Month 6 and Month 12 After Initiating OMB Treatment

Timeframe: From Baseline up to Month 6 and Month 12

Trial details

NCT IDNCT06737419

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-02-05

View on ClinicalTrials.gov More Multiple Sclerosis trials